PRISM BioLab Co. LTD (206A) AI Stock Analysis

• Market Cap: ¥6.18B
• Dividend Yield: N/A
• Average Volume (3M): 239.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 27
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -9.00
• Shares Outstanding: 36,790,000
• 10 Day Avg. Volume: 563,280
• 30 Day Avg. Volume: 239,103
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

PRISM BioLab Co. LTD faces significant challenges with declining revenue and profitability, contributing to a lower financial performance score. Technical indicators align with this challenging outlook, showing bearish trends. The absence of valuation metrics adds uncertainty to the stock's attractiveness. This results in a below-average overall stock score.

PRISM BioLab Co. LTD Business Overview & Revenue Model

Company Description

PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan.

How the Company Makes Money

PRISM BioLab generates revenue through the development and commercialization of its proprietary drug compounds. The company earns money by licensing its technology and compounds to pharmaceutical companies, securing milestone payments and royalties based on the success of these partnerships. Additionally, PRISM BioLab may engage in collaborative research and development agreements, which provide funding and shared expertise to advance its drug candidates. The company’s revenue model is heavily reliant on successful clinical trials and securing partnerships with larger pharmaceutical firms to bring its innovations to market.

PRISM BioLab Co. LTD Financial Statement Overview

Summary

PRISM BioLab Co. LTD is facing critical challenges with profitability and revenue generation. Despite a strong equity base and no debt, the company struggles with negative margins and declining revenue. The cash flow situation shows improvement, yet the company needs to address profitability issues to enhance financial health.

Income Statement

PRISM BioLab Co. LTD shows significant challenges in profitability with negative net income and EBIT across the periods. The company has a negative revenue growth rate of -44.88% from 2022 to 2023, indicating a substantial decline in revenue. Both gross profit and net profit margins are severely negative, suggesting high operational costs and inefficiencies.

Balance Sheet

The company maintains a strong equity position with zero debt, resulting in a debt-to-equity ratio of 0. The equity ratio remains robust at around 77.36% in 2024, indicating financial stability. However, the return on equity is negative due to sustained losses, which is a significant downside.

Cash Flow

Cash flow from operations has turned positive in 2024, a positive trend from the previous year. However, the free cash flow remains negative, and the free cash flow to net income ratio is not favorable due to substantial net losses. The overall cash position is strong, supported by significant cash inflows from financing activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	305.62M	112.93M	554.40M
Gross Profit	160.54M	80.31M	535.14M
EBITDA	-1.05B	-488.13M	67.89M
Net Income	-1.05B	-526.91M	72.96M
Balance Sheet
Total Assets	4.53B	1.21B	1.74B
Cash, Cash Equivalents and Short-Term Investments	4.39B	1.13B	1.69B
Total Debt	0.00	0.00	0.00
Total Liabilities	1.03B	63.41M	65.23M
Stockholders Equity	3.50B	1.15B	1.67B
Cash Flow
Free Cash Flow	-61.55M	-548.40M	97.25M
Operating Cash Flow	150.14M	-513.81M	102.96M
Investing Cash Flow	-244.19M	-40.38M	-7.87M
Financing Cash Flow	3.37B	0.00	110.87M

PRISM BioLab Co. LTD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 168.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Negative. The current price of 168 is below the 20-day moving average (MA) of 173.75, below the 50-day MA of 182.00, and below the 200-day MA of 244.90, indicating a bearish trend. The MACD of -4.56 indicates Negative momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 18.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:206A.

PRISM BioLab Co. LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4884	54 Neutral	¥3.07B	―	―	―	-8.56%	-7.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4594	47 Neutral	¥7.57B	―	―	―	1254.76%	33.94%
206A	45 Neutral	¥6.18B	―	―	―	―	―
4588	44 Neutral	¥17.51B	―	―	―	-9.04%	2.12%
4591	37 Underperform	¥4.93B	―	―	―	-59.53%	11.70%
4598	28 Underperform	¥6.09B	―	―	―	―	20.41%